Establishment of the National HBV Drug Resistance Monitoring Network and the current status of HBV drug resistance in China
ZENG Yi-jun,SUN Li-na,LIU Xue-en,ZHANG Ji-ming,SUN Jian,XU Dong-ping,HUANG Li-hua,LU Zhong-hua,ZHANG Shu-qin,LONG Bo,LIU Yun-hua,CHEN Shi-jun,ZHU Tong-hai,LIU Jin-tang,WANG Mao-rong,WANG Hai-jian,ZHANG Yue-xin,HAO Pei,HAN Yue,YU De-min,ZHANG Dong-hua,ZHANG Xin-xin,ZHUANG Hui
DOI: https://doi.org/10.16505/j.2095-0136.2013.03.012
2013-01-01
Abstract:Objective To establish the National Hepatitis B Virus(HBV)Drug Resistance Monitoring Network in accordance with the national "Eleventh Five-Year Major Projects" for the research of infectious diseases and to study anti-HBV drug resistance among patients with chronic hepatitis B(CHB)in China.Methods With bioinformatics and network information techniques,the "National HBV Drug Resistance Monitoring Network" was established in China and the current characteristics of HBV resistant mutations was analyzed.Results An extensive database of HBV drug resistance network was established in China.By the end of December 2012,a total of 9 998 CHB patients have been detected drug-resistant mutations and among which,2 421 were categorized as HBV genotype B,5 088 as genotype C,and 42 as genotype D.Of all HBV strains,5 207 were found drug-resistant related mutations with 3 700 in genotype C and 1 482 in genotype B.The frequency of drug resistance mutations in patients infected by HBV genotype C(3 700/5 207,72.72%)is higher than that by genotype B(1 482/2 421,61.21%)(P<0.01).Among all primary drug resistance mutations,the detection rate of major drug resistance is 43.64% and of which,M204I,A181T,A181V and rtA181T(sW172*)mutations are common in patients infected with HBV genotype C(P<0.05),but N236T mutation is more frequent in patients with HBV genotype B(P<0.01).M204V shows higher frequency than M204I in ETV-resistant related mutations(P<0.01).The detection rate of multi-drug resistance is up to 1.73%(131/7 551).Conclusions The National HBV Drug Resistance Network in China has been established for monitoring,sharing and standardizing the current HBV drug resistance status.The major HBV DNA mutations of antiviral resistance are associated with HBV genotypes.